Paid Clinical Trials in Grosse Pointe Woods, MI
As of June 2026, 43 paid clinical trials are recruiting in Grosse Pointe Woods, Michigan. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Grosse Pointe Woods offers studies at sites including Henry Ford Saint John Hospital - Academic for conditions such as Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Grosse Pointe Woods
Trials by drug in Grosse Pointe Woods
Filter results
43 clinical trials
↓ Download CSVUsing Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Mobile Health for Adherence in Breast Cancer Patients
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
About research studies in Grosse Pointe Woods
Grosse Pointe Woods has approximately 43 recruiting research studies across a wide range of therapeutic areas. Michigan hosts University of Michigan Health, Henry Ford Health, and Corewell Health, running trials across oncology, neurology, and cardiology with a strong focus on precision medicine.
Top Research Study Locations in Grosse Pointe Woods
Researchers run research studies in Grosse Pointe Woods, MI at 10 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Henry Ford Saint John Hospital - Academic | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 33 |
| Henry Ford Saint John Hospital - Breast | Stage IIIB Lung Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 32 |
| Henry Ford Saint John Hospital - Van Elslander | Anatomic Stage II Breast Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 32 |
| Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Anatomic Stage IV Breast Cancer AJCC v8, Cardiotoxicity, Castration-Resistant Prostate Carcinoma | 5 |
| Academic Hematology Oncology Specialists | Anatomic Stage IV Breast Cancer AJCC v8, Cardiotoxicity, Elevated CA15-3 or CEA or CA27-29 | 3 |
| Henry Ford St. John Hospital | COVID-19 SARS-CoV-2 Infection, Multiple Myeloma | 2 |
| Michigan Breast Specialists-Grosse Pointe Woods | Anatomic Stage IV Breast Cancer AJCC v8, Cardiotoxicity, Elevated CA15-3 or CEA or CA27-29 | 2 |
| Ascension | Triple Negative Breast Cancer | 1 |
| Henry Ford St John TM Center for Infectious Disease Research | Coronavirus Disease (COVID-19) | 1 |
| St. John Hospital | Breast Cancer | 1 |
Active & Upcoming Studies in Grosse Pointe Woods (2026)
Recruiting trials in Grosse Pointe Woods grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (36 active studies)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · Alliance for Clinical Trials in Oncology
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study · Phase 2 · SWOG Cancer Research Network
Vaccines (2 active studies)
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease · Phase 3 · Pfizer
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) · Phase 3 · Merck Sharp & Dohme LLC
Common conditions studied in Grosse Pointe Woods
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Breast Cancer (3 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Stage IIIB Lung Cancer AJCC v8 (3 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Anatomic Stage IIIB Breast Cancer AJCC v8 (2 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Anatomic Stage IV Breast Cancer AJCC v8 (2 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
Leading research sponsors in Grosse Pointe Woods
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
Local regulations and guidelines
Clinical trials in Michigan are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Michigan research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Grosse Pointe Woods. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Grosse Pointe Woods
Hipa.ai aggregates every recruiting study in Grosse Pointe Woods from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Grosse Pointe Woods?
There are approximately 43 recruiting clinical trials in Grosse Pointe Woods, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Grosse Pointe Woods pay participants?
Most recruiting trials in Grosse Pointe Woods compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Grosse Pointe Woods?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Grosse Pointe Woods?
The most common conditions under active study in Grosse Pointe Woods include Anatomic Stage II Breast Cancer AJCC v8 (3), Breast Cancer (3), Stage IIIB Lung Cancer AJCC v8 (3), Anatomic Stage IIIA Breast Cancer AJCC v8 (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Grosse Pointe Woods?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Grosse Pointe Woods on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Grosse Pointe Woods?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Grosse Pointe Woods?
Recruiting research sites in Grosse Pointe Woods include Henry Ford Saint John Hospital - Academic, Henry Ford Saint John Hospital - Breast, Henry Ford Saint John Hospital - Van Elslander, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Grosse Pointe Woods right now?
The largest active categories in Grosse Pointe Woods are Cancer & tumors (36), Vaccines (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.